TOPRAZOLE 40/MG EC TAB 15/TAB

Indications

Approved Uses

Erosive esophagitis associated with GERD (healing and maintenance of healing) and pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).

Off-Label Uses

Common off‑label uses include H. pylori eradication as part of combination therapy, prevention/treatment of NSAID‑associated ulcers, stress‑ulcer prophylaxis in critically ill patients, Barrett’s esophagus/GERD symptom control strategies, laryngopharyngeal reflux, and functional dyspepsia.

Dosage & Administration

Dosing by Condition

Erosive esophagitis (healing): 40 mg PO once daily for up to 8 weeks (may extend to another 8 weeks if needed). Maintenance of healed erosive esophagitis: 40 mg PO once daily. Pathological hypersecretory conditions (e.g., Zollinger-Ellison): start 40 mg PO twice daily and titrate to clinical response (doses up to 240 mg/day have been used). H. pylori eradication and NSAID-ulcer prevention: may be used in practice as part of combination/ulcer prophylaxis regimens but are generally off‑label depending on local labeling.

Initial Dose

40 mg once daily

Maintenance Dose

20-40 mg once daily

Maximum Dose

240 mg/day (Zollinger-Ellison syndrome); 80 mg/day for standard indications

Children's Dosage

Approved for children 5 years and older for erosive esophagitis. 15kg to <40kg: 20mg once daily for up to 8 weeks. ≥40kg: 40mg once daily for up to 8 weeks.

Dose Adjustment Notes

Renal impairment: no dosage adjustment required. Hepatic impairment: no adjustment in mild-moderate; in severe hepatic impairment, use with caution and consider dose reduction/monitoring (some references limit to 20 mg/day), especially for prolonged therapy.

How to Take

Swallow the 40 mg enteric‑coated tablet whole with water; do not crush, chew, or split. Take once daily preferably 30-60 minutes before a meal (commonly before breakfast); if prescribed twice daily, take before morning and evening meals.

Side Effects

Common Side Effects

Headache, diarrhea, abdominal pain, nausea, vomiting, flatulence, dizziness, joint pain.

Safety & Warnings

Contraindications

Hypersensitivity to pantoprazole/other substituted benzimidazoles (PPIs) or excipients; concomitant use with rilpivirine-containing products.

Warnings & Precautions

May mask gastric malignancy-evaluate alarm symptoms; risk of C. difficile diarrhea; long-term therapy risks: hypomagnesemia (consider monitoring esp. with diuretics/digoxin), vitamin B12 deficiency, osteoporosis-related fractures, fundic gland polyps; acute interstitial nephritis; cutaneous/systemic lupus-discontinue if suspected.

Age Restriction

Not approved for children <5 years for erosive esophagitis; pediatric use is indication- and age-dependent (typically ≥5 years for EE, and ≥1 year for certain GERD indications depending on local labeling).

Drug Interactions

Interaction Severity

MAJOR/CONTRAINDICATED: rilpivirine; avoid with atazanavir or nelfinavir (reduced absorption/virologic failure risk). MODERATE: warfarin (INR changes-monitor), high‑dose methotrexate (delayed clearance/toxicity-consider holding PPI), drugs needing acidic pH for absorption such as ketoconazole/itraconazole/posaconazole suspension and iron salts (reduced absorption). MINOR/variable: digoxin (possible increased levels via hypomagnesemia), mycophenolate (reduced exposure in some patients).

Food Interaction

Administer 30-60 minutes before a meal for optimal effect; food may delay absorption and can reduce the timing/extent of acid suppression, so consistent pre‑meal dosing is recommended.

Special Populations

Pregnancy

Category B (old US system); use during pregnancy only if clearly needed

Children

Approved for children 5 years and older for erosive esophagitis. 15kg to <40kg: 20mg once daily for up to 8 weeks. ≥40kg: 40mg once daily for up to 8 weeks.

Elderly

Standard adult dosing; no routine dose adjustment required. Use the lowest effective dose for the shortest duration necessary.

Kidney Impairment

No adjustment needed for renal impairment.

Storage & Patient Advice

Stopping the Medicine

If used long-term, consult prescriber before stopping; rebound acid hypersecretion can occur-consider tapering/step-down rather than abrupt cessation in chronic users.

Patient Counseling

Swallow the enteric‑coated tablet whole with water (do not crush/chew/split) and take 30-60 minutes before a meal at the same time each day; symptom relief may start in 1 day but full effect can take several days. Seek care for severe/persistent diarrhea, rash, new/worsening joint pain, or signs of low magnesium (cramps, palpitations); with long‑term use discuss fracture risk and possible low magnesium/vitamin B12. Tell clinicians about all medicines, especially HIV therapy (rilpivirine/atazanavir/nelfinavir), warfarin, methotrexate, and azole antifungals/iron.

Monitoring Requirements

Long‑term therapy: consider periodic magnesium (especially with diuretics/digoxin) and assess for vitamin B12 deficiency if prolonged use; consider bone fracture risk in at‑risk patients; monitor INR/PT when used with warfarin; monitor for persistent diarrhea (C. difficile) and renal injury symptoms (AIN).

Pharmacology

Mechanism of Action

Inhibits the final step in gastric acid production by irreversibly binding to the H+/K+ ATPase pump (proton pump) in gastric parietal cells, suppressing both basal and stimulated acid secretion.

Onset of Action

Onset begins within a few hours after the first dose (about 2-3 hours), but maximal acid suppression typically occurs after 3-4 days of daily dosing.

Duration of Effect

Approximately 24 hours of acid suppression with once‑daily dosing (though maximal effect requires several days of continuous dosing).

Bioavailability

Approximately 77%.

Metabolism

Hepatic metabolism primarily via CYP2C19 with a smaller contribution from CYP3A4; pantoprazole has low potential for clinically significant CYP induction/inhibition at therapeutic doses.

Excretion

Approximately 71% excreted in urine as metabolites and about 18% in feces.

Protein Binding

Approximately 98%, mainly to albumin.

Product Information

Available Dosage Forms

For this SFDA product: enteric‑coated tablet (oral) 40 mg. (Pantoprazole also exists in other markets as IV powder for injection and oral granules/suspension, but those are different products.)

Composition per Dose

Each enteric-coated tablet: 40mg pantoprazole (as pantoprazole sodium sesquihydrate).

OTC Alternatives

OTC alternatives for acid symptoms (market-dependent) include antacids (aluminum/magnesium hydroxide, calcium carbonate), H2 blockers (e.g., famotidine), and in some countries OTC PPIs (e.g., omeprazole 20 mg).

Gi Condition

Acid Reflux/GERD, Ulcer

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.